Thursday, October 15, 2026

Target Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 20, 2020

Target Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Target Corporation

6.7% sales growth and 30.74% return on equity

Target Corporation operates as a general merchandise retailer in the United States.

Target Corporation's sales growth this year is expected to be 17.6% and a negative 3.1% for next year.

Year-on-year quarterly revenue growth grew by 21.3%, now sitting on 88.62B for the twelve trailing months.

Target Corporation's sales growth for the next quarter is 6.7%. The company's growth estimates for the present quarter and the next is 33.7% and 211.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 30.74%.

Target Corporation's Stock Yearly Top and Bottom Value

Target Corporation's stock is valued at $171.71 at 10:22 EST, below its 52-week high of $181.17 and way above its 52-week low of $90.17.

Target Corporation's Moving Average

Target Corporation's worth is above its 50-day moving average of $166.01 and way above its 200-day moving average of $143.84.

2. Zynex, Inc.

86.2% sales growth and 28.99% return on equity

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Zynex, Inc.'s sales growth this year is expected to be 76.3% and 78.2% for next year.

Year-on-year quarterly revenue growth grew by 69.5%, now sitting on 68.68M for the twelve trailing months.

Zynex, Inc.'s sales growth for the next quarter is 86.2%. The company's growth estimates for the current quarter and the next is a negative 33.3% and negative -11.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.99%.

Zynex, Inc.'s Stock Yearly Top and Bottom Value

Zynex, Inc.'s stock is valued at $14.00 at 10:22 EST, way under its 52-week high of $29.73 and way higher than its 52-week low of $7.51.

Zynex, Inc.'s Moving Average

Zynex, Inc.'s worth is above its 50-day moving average of $13.55 and way below its 200-day moving average of $17.59.

3. Tempur Sealy International, Inc.

8.2% sales growth and 63.13% return on equity

Tempur Sealy International, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes bedding products in the United States, Canada, and internationally.

Tempur Sealy International, Inc.'s sales growth this year is anticipated to be 16.1% and 8.2% for next year.

Year-on-year quarterly revenue growth grew by 37.9%, now sitting on 3.49B for the twelve trailing months.

Tempur Sealy International, Inc.'s sales growth for the next quarter is 8.2%. The company's growth estimates for the ongoing quarter and the next is 44.1% and 21.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 63.13%.

Tempur Sealy International, Inc.'s Stock Yearly Top and Bottom Value

Tempur Sealy International, Inc.'s stock is valued at $26.35 at 10:22 EST, under its 52-week high of $26.55 and way higher than its 52-week low of $5.50.

Tempur Sealy International, Inc.'s Moving Average

Tempur Sealy International, Inc.'s worth is above its 50-day moving average of $24.00 and way above its 200-day moving average of $21.14.

4. Lumentum Holdings Inc.

5.6% sales growth and 9.18% return on equity

Lumentum Holdings Inc. manufactures and sells optical and photonic products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa.

Lumentum Holdings Inc.'s sales growth this year is expected to be 7.1% and 9.9% for next year.

Year-on-year quarterly revenue growth grew by 0.6%, now sitting on 1.68B for the twelve trailing months.

Lumentum Holdings Inc.'s sales growth is a negative 0% for the present quarter and 5.6% for the next. The company's growth estimates for the current quarter and the next is 19% and 3.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.18%.

Lumentum Holdings Inc.'s Stock Yearly Top and Bottom Value

Lumentum Holdings Inc.'s stock is valued at $93.01 at 10:22 EST, under its 52-week high of $96.74 and way higher than its 52-week low of $59.06.

Lumentum Holdings Inc.'s Moving Average

Lumentum Holdings Inc.'s value is above its 50-day moving average of $85.54 and way higher than its 200-day moving average of $82.42.

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com